The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Icelandic biosimilars company and Humira (adalimumab) challenger Alvotech has scored a major win in a lawsuit brought by AbbVie, alleging theft of trade secrets. 8 October 2021
Fortress Biotech subsidiary Cyprium Therapeutics, with support from its licensing partner Sentynl Therapeutics, which is wholly-owned by India’s Cadila Healthcare, today announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histidinate (CuHis). 8 October 2021
US drugmaker Bristol Myers Squibb has sought to portray a Phase II failure for deucravacitinib as a rare setback for its selective tyrosine kinase 2 (TYK2) inhibitor. 8 October 2021
Carima Andrady, senior regulatory writer at PharmaLex, provides an Expert View on a key consideration when seeking to secure an Orphan Drug designation (ODD) in Europe. 8 October 2021
The US Food and Drug Administration’s Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. 8 October 2021
AbbVie yesterday announced positive top-line results from the first of two studies of the Phase III SELECT-AXIS 2 clinical trial evaluating the efficacy and safety of Rinvoq (upadacitinib; 15mg, once daily) in patients with active ankylosing spondylitis (AS) who had an inadequate response to biologic DMARD therapy. 8 October 2021
Shares of US clinical-stage biotech Allogene Therapeutics plunged more than 40% in after-hours trading yesterday, following its revelation of a Food and Drug Administration hold on the company’s AlloCAR T clinical trials. 8 October 2021
At a meeting this month, an Institute for Clinical and Economic Review (ICER) committee will assess the comparative clinical effectiveness and value of Bristol Myers Squibb’s mavacamten for the treatment of hypertrophic cardiomyopathy (HCM). 7 October 2021
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics and US drug developer Enzolytics have signed a strategic CDMO partnership agreement. 7 October 2021
Canada-based ImmunoPrecise Antibodies (TSX Venture: IPA) and French drugmaker Pierre Fabre today announced that IPA's subsidiary, Talem Therapeutics and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. 7 October 2021
Swiss privately-held ophthalmics company Oculis has appointed Dr Joanne Chang as chief medical officer and head of portfolio management. 7 October 2021
UK-based medical cannabis R&D company Kanabo Group has signed a partnership agreement with MedoCann Pharma for the development of unique new products with exclusive distribution rights into the German and UK markets. 7 October 2021
Neumora Therapeutics, a US clinical-stage biotech focussed on brain diseases through the integration of data science and neuroscience, announced its launch today. 7 October 2021
Privately-held Danish vaccines company MinervaX has provided an update on clinical progress and announced changes to its executive and scientific advisory boards. 7 October 2021
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with inadequate response to existing therapies. 7 October 2021
UK pharma major GlaxoSmithKline (LSE: GSK), having largely missed out in the race for COVID-19 vaccines, has scored a goal in the fight against a malaria. 7 October 2021
Swedish drugmaker Calliditas Therapeutics has now taken full control of France-headquartered Genkyotex, a leader in NOX inhibition therapies, after the completion of a centralized squeeze out offer to all minority shareholders. 7 October 2021
The value of US gene therapy company Voyager Therapeutics doubled in Wednesday’s early trading following news of a deal with the world’s largest pharma company. 6 October 2021